Osteoporosis, Androgen Levels and Urological Care

Journal of Urology

Volumn 183, Issue 6, 2010, Pages 2122-2123

  Adler, Robert A ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; GONADORELIN DERIVATIVE; LONG ACTING DRUG; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ADD ON THERAPY; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BONE DENSITY; DIET SUPPLEMENTATION; DRUG INDICATION; EDITORIAL; FRACTURE; HUMAN; HYPOGONADISM; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL; UROLOGICAL CARE; VITAMIN D DEFICIENCY;

FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 77951879435     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.048     Document Type: Editorial

References (8)

1. Adler R.A., Hastings F.W., and Petkov V.I. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX. Osteoporos Int 21 (2010) 647
2. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation therapy for prostate cancer. N Engl J Med 352 (2005) 154
3. Smith M.R., Goode M., Zietman A.L., et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 22 (2004) 2546
4. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008
5. Smith M.R., Malkowicz S.B., Chu F., et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179 (2008) 152
6. Greenspan S.L. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 93 (2008) 2
7. Smith M.R., Saad F., Egerdie B., et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 182 (2009) 2670
8. ™ algorithm and Garvan nomogram. Osteoporos Int (2009) Epub ahead of print